Business Wire

1. US FDA Grants Orphan Drug And Rare Pediatric Disease Designations To GEn1E Lifesciences' Dual Signal Modulator For The Treatment Of Duchenne Muscular Dystrophy 6/10/2026

   GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision medicines for immunology, inflammation, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to GEn-1123 for the treatment of Duchenne Muscular Dystrophy (DMD).

2. Perpetual Medicines And Third Rock Ventures Deliver A Development Candidate In Under 18 Months Via Computational Physics And AI-Driven Platform 6/9/2026

   Perpetual Medicines, a biotechnology company pioneering the integration of computational physics and artificial intelligence for complex drug discovery, today announced the successful delivery of a development candidate in collaboration with Third Rock Ventures.

3. OpenFold Consortium Adds Eleven New Members As Momentum Builds For Open AI Infrastructure In Biology And Drug Discovery 6/9/2026

   OpenFold Consortium, an open science initiative advancing open-source AI tools for biology and drug discovery, announced today that eleven new members have joined the consortium including Absci, Adaptive Biotechnologies, Benchling, Chemical Computing Group, Daiichi Sankyo, Flagship Pioneering, Kiin Bio, Nanome, Nxera, Pledge Tx, and Superluminal.

4. Owkin To Build AI Agents As Part Of A Multi-Year K Pro Collaboration With Sanofi 6/5/2026

   Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist.

5. Chai Discovery Announces License Agreement With Pfizer To Accelerate Drug Discovery With AI 6/4/2026

   Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.

6. Terremoto Biosciences Granted FDA Fast Track Designation For TER-2013, An AKT1-Selective Small Molecule Inhibitor For Breast Cancer 6/3/2026

   Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TER-2013, the Company’s lead AKT1-selective inhibitor, in patients with locally advanced, unresectable or metastatic HR+/HER2- breast cancer harboring one or more AKT/PI3K/PTEN alterations following progression on at least one endocrine-based therapy and CDK4/6 inhibitor for advanced disease.

7. Sanofi Chooses Snowflake To Accelerate Its AI-Powered Drug Development 6/2/2026

   SNOWFLAKE SUMMIT 26 – Snowflake, the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit.

8. Biocytogen Launches AI-Powered RenSuper Platform And Industry-First Fully Automated Antibody Discovery Infrastructure 5/26/2026

   Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production.

9. Curi Bio Launches The Curiverse At MPS 2026: The Industry's First Closed-Loop Ecosystem For Industrial-Scale, Human-Relevant Drug Discovery 5/26/2026

   Curi Bio, a global leader in functional human biology, today unveiled the Curiverse at the Microphysiological Systems World Summit (MPS) 2026, the industry’s first closed-loop ecosystem unifying assay-ready iPSC-derived cells, automated high-throughput systems, and cloud-based data analytics for industrial-scale 3D human drug discovery.

10. Incyte And Genesis Expand Molecular AI Collaboration To Accelerate Drug Discovery 5/20/2026

    Incyte and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte.